Human γδ T Cell Subsets and Their Clinical Applications for Cancer Immunotherapy

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Jun 24

PMID 35740670

Authors

Derek Lee

Carl J Rosenthal

Natalie E Penn

Zachary Spencer Dunn

Yang Zhou

Lili Yang

Affiliations

Soon will be listed here.

Abstract

Gamma delta (γδ) T cells are a minor population of T cells that share adaptive and innate immune properties. In contrast to MHC-restricted alpha beta (αβ) T cells, γδ T cells are activated in an MHC-independent manner, making them ideal candidates for developing allogeneic, off-the-shelf cell-based immunotherapies. As the field of cancer immunotherapy progresses rapidly, different subsets of γδ T cells have been explored. In addition, γδ T cells can be engineered using different gene editing technologies that augment their tumor recognition abilities and antitumor functions. In this review, we outline the unique features of different subsets of human γδ T cells and their antitumor properties. We also summarize the past and the ongoing pre-clinical studies and clinical trials utilizing γδ T cell-based cancer immunotherapy.

Citing Articles

γδ T Are Significantly Impacted by CLL Burden but Only Mildly Influenced by M-MDSCs.

Zarobkiewicz M, Kowalska W, Szymanska A, Lehman N, Kowalczyk B, Tomczak W Cancers (Basel). 2025; 17(2).

PMID: 39858035 PMC: 11763719. DOI: 10.3390/cancers17020254.

Impact of perinatal factors on T cells and transcriptomic changes in preterm infant brain injury.

Zhang X, Yang Y, Xu Y, Chen L, Niu M, Zhu J J Neuroinflammation. 2024; 21(1):310.

PMID: 39614291 PMC: 11607874. DOI: 10.1186/s12974-024-03311-4.

Effect of Cyclin-Dependent Kinase 4/6 Inhibitors on Circulating Cells in Patients with Metastatic Breast Cancer.

Lobo-Martins S, Corredeira P, Cavaco A, Rodrigues C, Piairo P, Lopes C Cells. 2024; 13(16).

PMID: 39195280 PMC: 11487375. DOI: 10.3390/cells13161391.

TFEB controls sensitivity to chemotherapy and immuno-killing in non-small cell lung cancer.

Akman M, Monteleone C, Doronzo G, Godel M, Napoli F, Merlini A J Exp Clin Cancer Res. 2024; 43(1):219.

PMID: 39107857 PMC: 11304671. DOI: 10.1186/s13046-024-03142-4.

The use of peripheral CD3γδVδ2 T lymphocyte cells in combination with the ALBI score to predict immunotherapy response in patients with advanced hepatocellular carcinoma: a retrospective study.

Zhang S, Li L, Liu C, Pu M, Ma Y, Zhang T J Cancer Res Clin Oncol. 2024; 150(7):365.

PMID: 39052085 PMC: 11272815. DOI: 10.1007/s00432-024-05896-y.

References

Marcu-Malina V, Heijhuurs S, van Buuren M, Hartkamp L, Strand S, Sebestyen Z . Redirecting αβ T cells against cancer cells by transfer of a broadly tumor-reactive γδT-cell receptor. Blood. 2011; 118(1):50-9. DOI: 10.1182/blood-2010-12-325993. View

Scotet E, Nedellec S, Devilder M, Allain S, Bonneville M . Bridging innate and adaptive immunity through gammadelta T-dendritic cell crosstalk. Front Biosci. 2008; 13:6872-85. DOI: 10.2741/3195. View

Fowler D, Copier J, Dalgleish A, Bodman-Smith M . Zoledronic acid renders human M1 and M2 macrophages susceptible to Vδ2 γδ T cell cytotoxicity in a perforin-dependent manner. Cancer Immunol Immunother. 2017; 66(9):1205-1215. PMC: 5579165. DOI: 10.1007/s00262-017-2011-1. View

Deusch K, Luling F, Reich K, Classen M, Wagner H, Pfeffer K . A major fraction of human intraepithelial lymphocytes simultaneously expresses the gamma/delta T cell receptor, the CD8 accessory molecule and preferentially uses the V delta 1 gene segment. Eur J Immunol. 1991; 21(4):1053-9. DOI: 10.1002/eji.1830210429. View

Bennouna J, Bompas E, Neidhardt E, Rolland F, Philip I, Galea C . Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother. 2008; 57(11):1599-609. PMC: 11030608. DOI: 10.1007/s00262-008-0491-8. View

Saveanu L, Carroll O, Weimershaus M, Guermonprez P, Firat E, Lindo V . IRAP identifies an endosomal compartment required for MHC class I cross-presentation. Science. 2009; 325(5937):213-7. DOI: 10.1126/science.1172845. View

Castella B, Foglietta M, Sciancalepore P, Rigoni M, Coscia M, Griggio V . Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma. Oncoimmunology. 2015; 4(11):e1047580. PMC: 4589055. DOI: 10.1080/2162402X.2015.1047580. View

Chen Y, Song Y, Du W, Gong L, Chang H, Zou Z . Tumor-associated macrophages: an accomplice in solid tumor progression. J Biomed Sci. 2019; 26(1):78. PMC: 6800990. DOI: 10.1186/s12929-019-0568-z. View

Wilhelm M, Smetak M, Schaefer-Eckart K, Kimmel B, Birkmann J, Einsele H . Successful adoptive transfer and in vivo expansion of haploidentical γδ T cells. J Transl Med. 2014; 12:45. PMC: 3926263. DOI: 10.1186/1479-5876-12-45. View

10.

Lang J, Kaikobad M, Wallace M, Staab M, Horvath D, Wilding G . Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma. Cancer Immunol Immunother. 2011; 60(10):1447-60. PMC: 3177972. DOI: 10.1007/s00262-011-1049-8. View

11.

Abe Y, Muto M, Nieda M, Nakagawa Y, Nicol A, Kaneko T . Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma. Exp Hematol. 2009; 37(8):956-68. DOI: 10.1016/j.exphem.2009.04.008. View

12.

Leslie D, Vincent M, Spada F, Das H, Sugita M, Morita C . CD1-mediated gamma/delta T cell maturation of dendritic cells. J Exp Med. 2002; 196(12):1575-84. PMC: 2196072. DOI: 10.1084/jem.20021515. View

13.

Papadopoulou M, Tieppo P, McGovern N, Gosselin F, Chan J, Goetgeluk G . TCR Sequencing Reveals the Distinct Development of Fetal and Adult Human Vγ9Vδ2 T Cells. J Immunol. 2019; 203(6):1468-1479. DOI: 10.4049/jimmunol.1900592. View

14.

Kenna T, Golden-Mason L, Norris S, Hegarty J, OFarrelly C, Doherty D . Distinct subpopulations of gamma delta T cells are present in normal and tumor-bearing human liver. Clin Immunol. 2004; 113(1):56-63. DOI: 10.1016/j.clim.2004.05.003. View

15.

Kunzmann V, Smetak M, Kimmel B, Weigang-Koehler K, Goebeler M, Birkmann J . Tumor-promoting versus tumor-antagonizing roles of γδ T cells in cancer immunotherapy: results from a prospective phase I/II trial. J Immunother. 2012; 35(2):205-13. DOI: 10.1097/CJI.0b013e318245bb1e. View

16.

Luoma A, Castro C, Adams E . γδ T cell surveillance via CD1 molecules. Trends Immunol. 2014; 35(12):613-621. PMC: 4383740. DOI: 10.1016/j.it.2014.09.003. View

17.

Blackburn S, Shin H, Nicholas Haining W, Zou T, Workman C, Polley A . Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2008; 10(1):29-37. PMC: 2605166. DOI: 10.1038/ni.1679. View

18.

Willcox C, Davey M, Willcox B . Development and Selection of the Human Vγ9Vδ2 T-Cell Repertoire. Front Immunol. 2018; 9:1501. PMC: 6036166. DOI: 10.3389/fimmu.2018.01501. View

19.

McVay L, Carding S . Extrathymic origin of human gamma delta T cells during fetal development. J Immunol. 1996; 157(7):2873-82. View

20.

Pressey J, Adams J, Harkins L, Kelly D, You Z, Lamb Jr L . In vivo expansion and activation of γδ T cells as immunotherapy for refractory neuroblastoma: A phase 1 study. Medicine (Baltimore). 2016; 95(39):e4909. PMC: 5265919. DOI: 10.1097/MD.0000000000004909. View